Streetbeat News

Products Services

CNX

NuBlu Energy and CNX Resources Corp. (NYSE:CNX) have announced a partnership to revolutionize the CNG and micro-scale LNG industries with the introduction of ZeroHP CNG and Clean mLNG technologies. These innovations aim to produce compressed natural gas and micro-scale liquefied natural gas more efficiently and with a lower cost and carbon footprint. The technologies leverage Geobaric Energy and methane-only refrigeration, potentially displacing traditional diesel, kerosene, and propane uses, and significantly reducing carbon emissions. This partnership could transform energy production and usage, particularly in the Appalachian region, by offering cleaner, more affordable energy solutions.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:39 pm

PRQR

ProQR Therapeutics announced its plans to present on Axiomer RNA editing technology at the ASGCT 27th Annual Meeting. This presentation could highlight significant advancements in RNA editing, potentially impacting the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:39 pm

CLLS

Cellectis announced it will present data on its TALEN gene-editing process at the American Society of Gene & Cell Therapy (ASGCT) meeting from May 7-11. This presentation could highlight advancements in gene editing technology and potentially impact Cellectis' position in the biotech industry.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:38 pm

TOVX

Theriva Biologics will present preclinical data at the American Society for Cell and Gene Therapy 27th Annual Meeting, showing that its lead product candidate, VCN-01, in combination with liposomal irinotecan, demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft. This synergy highlights VCN-01's potential in various chemotherapy combinations for improved pancreatic cancer treatment efficacy.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:37 pm

SGMO

Sangamo Therapeutics announced it will present neurology-focused pre-clinical data from its epigenetic regulation, capsid delivery, and genome engineering platforms at the 27th ASGCT Annual Meeting. This showcases the company's advancements in gene therapy and its potential impact on treating neurological disorders.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:36 pm

ACET

Adicet Bio, Inc. presented an abstract at the ASGCT 27th Annual Meeting, featuring preclinical data for ADI-270, highlighting its potential in clinical applications.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:33 pm

VYGR

Voyager Therapeutics announced its plan to present translational data for its intravenous-delivered, central nervous system (CNS) gene therapy programs, which are advancing toward clinical trials, at the ASGCT 27th Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:31 pm

PKG

Packaging Corporation Of America (PKG) anticipates Q2 EPS of $2.07, below the estimated $2.22. The company cites strong orders in its Paper segment but expects lower volume due to maintenance at its International Falls, MN mill. Despite implementing price increases, average prices and mix may be slightly lower due to earlier index price decreases affecting contract triggers with some customers.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:20 pm

CHDN

EA

SOLUSD

Ian Cummings, a gaming veteran with experience at Electronic Arts, Zynga, and FanDuel, has led the development of Photo Finish LIVE, a play-to-earn virtual horse racing game under Third Time Entertainment. The game, which utilizes Solana blockchain for its NFTs, offers a new Web3 experience for horse racing enthusiasts, allowing players to race, breed, and stake horses. Cummings aims to attract a broad audience, leveraging his extensive background in gaming. The game has partnered with Churchill Downs, Inc. for a Virtual Kentucky Derby event, aiming for further growth and expansion, including a mobile app launch and obtaining a gambling license in more countries.

Portfolio Pulse from Chris Katje

April 22, 2024 | 8:18 pm

ABEO

Abeona Therapeutics announced that a recent letter they received did not identify any deficiencies related to clinical efficacy or clinical safety data in their Biologics License Application (BLA).

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:12 pm